OncoHost Raises $35 Million To Utilize ML In Cancer Treatment
OncoHost has raised $35 million in a Series C funding round, hoping to continue to expand their machine-learning based cancer treatment system, PROphet.
Created on May 10|Last edited on May 10
Comment
Cancer is a deadly and complex disease, and because of this, treatment can vary wildly from patient to patient; Cancer type, body type, progression, age, there are so many factors that make cancer treatment a complicated mess. Time isn't on patients' side when facing this disease, so OncoHost has stepped up to the plate to quicken these processes.
OncoHost is a company developing technology called PROphet that is able to quickly and accurately determine the best treatment for patients, personalized to their situation. The technology is powered by machine learning and is able to predict the most effective treatment for it's patients by leveraging it's model trained on existing data and outcomes. Through a process of blood sampling and analysis to determine a patient profile, then running the profile through the machine learning model, a prediction for the optimal treatment is produced.
Who's funding OncoHost and where's the money going?
OncoHost raised $35 million thanks to a Series C funding round led by ALIVE Isreal HealthTech Fund with additional participation from Leumi Partners, Menora Mivtachim, and OurCrowd.
The money will be used to continue funding and expanding the ongoing trials using PROphet, as well as facilitating the launch of their products in the US.
Find out more
Add a comment
Tags: ML News
Iterate on AI agents and models faster. Try Weights & Biases today.